Financing ·
TFA Therapeutics, Inc. announced the approval and authorization of an offshore private placement offering up to $15…
RAJAFTFA Therapeutics, Inc.
TFA Therapeutics, Inc. announced the approval and authorization of an offshore private placement offering up to $15 million in aggregate proceeds through rolling closings. The company is issuing ordinary shares at a fixed subscription price of $2.52 per share, targeting approximately $10 million from roughly 3.97 million shares, with a maximum capacity of 5.95 million shares. Proceeds are intended to advance the development and regulatory activities of TFA-01, including chemistry, manufacturing, controls, nonclinical safety, clinical trials, and working capital needs. The offering is conducted exclusively with non-U.S. persons in offshore transactions pursuant to Regulation S, with no directed selling efforts in the United States. TFA Therapeutics operates in the biotechnology industry, focusing on drug development.